Hyperfine Inc. is a pioneering force in medical technology, renowned for developing the world’s first FDA-cleared portable MRI system, which significantly enhances diagnostic imaging accessibility at the point of care. By combining innovation with cost-efficiency, the company improves patient outcomes and facilitates rapid clinical decision-making. As healthcare continues to evolve, Hyperfine is strategically positioned to capture growth opportunities within the expanding imaging diagnostics market, presenting a compelling investment prospect for institutional investors focused on transformative healthcare solutions.
| Revenue (TTM) | $16.54M |
| Gross Profit (TTM) | $8.50M |
| EBITDA | $-32.50M |
| Operating Margin | -216.90% |
| Return on Equity | -97.00% |
| Return on Assets | -38.80% |
| Revenue/Share (TTM) | $0.18 |
| Book Value | $0.35 |
| Price-to-Book | 2.00 |
| Price-to-Sales (TTM) | 4.39 |
| EV/Revenue | 2.618 |
| EV/EBITDA | -0.72 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 44.80% |
| Shares Outstanding | $90.99M |
| Float | $86.42M |
| % Insiders | 4.44% |
| % Institutions | 22.59% |
Volatility is currently expanding
GUILFORD, Conn.--(BUSINESS WIRE)--CE mark and UKCA approvals support Swoop system Model 2 expansion as Hyperfine highlights portable MRI in brain health awareness efforts.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the third quarter 2026 on Monday, November 9, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recordi.
Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript
Hyperfine NASDAQ: HYPR reported second-quarter revenue of $3.9 million, up approximately 45% from a year earlier, as the portable MRI company cited growth across hospital, neurology office and international markets.
GUILFORD, Conn.--(BUSINESS WIRE)--Multiple peer-reviewed publications in Journal of Neurosurgery and Stroke strengthen evidence for portable MRI in stroke and neurosurgical settings.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine will report Q2 2026 financial results Thur., Aug. 6, 2026. Management will host a corresponding conference call at 1:30 PM PT/4:30 PM ET.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine initiates the launch of the next-gen Swoop® system in Europe, beginning global expansion of its most advanced portable MRI technology. .
GUILFORD, Conn.--(BUSINESS WIRE)--Leading neurosurgeons will help guide the role of the Swoop® system in neurosurgical care, including workflow, product capabilities, and evidence.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces Swoop® system scan volume milestones at key hospitals and neurology clinics, demonstrating accelerating adoption across the US.
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HYPR and any ticker you trade — then tracks every position and per-strategy win rate.
